[Monoclonal antibody therapy for non-Hodgkin's lymphoma].

@article{Paul2010MonoclonalAT,
  title={[Monoclonal antibody therapy for non-Hodgkin's lymphoma].},
  author={Franciane Paul and Jean François Rossi and Guillaume Cartron},
  journal={La Revue du praticien},
  year={2010},
  volume={60 1},
  pages={59-63}
}
Anti-CD20 monoclonal antibodies are currently used for non-Hodgkin's lymphoma treatment and Rituximab (MabThera) and ibritumomab-tiuxetan (Zevalin) currently approved for clinical use. Rituximab has improved survival of patients with follicular and diffuse large B cells lymphoma. Rituximab is safe with uncommon side effects mainly observed during the first… CONTINUE READING